BIOVENTUS INC - A
BVSNASDAQTrading Snapshot
- Day Range
- $14.73 β $15.09
- 52-Week Range
- $6.47 β $15.89
- Volume (shares)
- 444,907
- Avg Volume (shares)
- β
- Shares Outstanding
- 84.1M
- Next Earnings
- 2026-11-02
Fundamentals Snapshot
- Annual Revenue
- $568M
- Last Q Revenue
- $153M
- P/E Ratio
- 22.3
- P/S Ratio
- 2.1x
- EPS (TTM)
- $0.78
- Dividend Yield
- β
- Dilution (1yr)
- +5.3%
BIOVENTUS INC - A
BVSAbout BIOVENTUS INC - A
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The companyβs product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The companyβs restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates

Bioventus to Report Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026
DURHAM, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (βBioventusβ or the βCompanyβ), a global leader in innovations for active healing, today announced that it will report financial results for th

Bioventus Inc (BVS) Stock Up 3.6% but GF Value Says Overvalued -- GF Score: 63/100
On October 12, 2026, Bioventus Inc (BVS) shares rose 3.6% today, currently priced at $13.53. This move comes amid a 52-week range of $6.46 to $15.89.GF ValueΓ’ΒΒ’

Comparing Kestra Medical Technologies (NASDAQ:KMTS) & Bioventus (NASDAQ:BVS)
Bioventus (NASDAQ: BVS - Get Free Report) and Kestra Medical Technologies (NASDAQ: KMTS - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies base

Reviewing Bioventus (NASDAQ:BVS) & RxSight (NASDAQ:RXST)
RxSight (NASDAQ: RXST - Get Free Report) and Bioventus (NASDAQ: BVS - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength

Bioventus: Cash Flow Anchors The Bull Case Beyond A Potential Sale
Bioventus leverages cash from established products to reduce debt and fund commercial expansion, supporting a bullish outlook. BVS benefits from improved financing flexibility, with a term loan maturity extended to 2030

Are Medical Stocks Lagging Bioventus (BVS) This Year?
Here is how Bioventus (BVS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.